←
JTO & JTO CRR4,600 posts
JTO & JTO CRR avatar✓

JTO & JTO CRR ✓

@JTOonline

JTO & JTO CRR are the official journals of @IASLC & the source for information on detection, prevention, diagnosis & treatment of thoracic cancers. jtocrr.org

◷ Joined September 2010▧ 850 Photos and videos
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 4

What does 20 years of JTO mean to those who have helped shape its success? Associate Editor William Travis shares his reflections as we continue celebrating the journal's legacy and contributions to thoracic oncology. #JTO20 #IASLC

1:15
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 16

Celebrating a leader who has helped support scientific discovery and knowledge sharing for nine years. Thank you, Johan Vansteenkiste! #JTO20

Post attachment
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 16

As we reflect on two decades of JTO, we're grateful for contributors like Ramon Rami-Porta, whose seven years of service have left a lasting mark. #JTO20

Post attachment
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 13

What’s next for patients with platinum-refractory advanced B3 thymoma and thymic carcinoma? With no standard second-line treatment, new research is critical. Remon et al. share updated findings from the PECATI trial, now published in #JTO. Read more: bit.ly/3Xqcqra

Post attachment
Shreyas Kalantri, MD avatar
⟳ JTO & JTO CRR retweeted
Shreyas Kalantri, MD@KalantriShreyas·Nov 12

One of my final research projects from fellowship! We examined real-world adoption of first-line immunotherapy in advanced NSCLC over the past decade, finding substantial increases in uptake but persistent disparities across patient populations. Thank you @JTOonline for highlighting our work, and grateful to all my coauthors and collaborators!

Post attachment
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 13

#LDCT lung cancer screening has been an approved covered benefit for adults aged 55-77 years by the Centers for Medicare and Medicaid Services since 2015. Miller et al. sought to compare the cancer detection rates in a general population #lungcancer screening registry to the #NLST, which they found were comparable. Read the article here: bit.ly/4sObSaB #LungCancerResearch #JTO

Post attachment
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 10

Join us in recognizing Tetsuya Mitsudomi for nine years of service and his contributions to JTO's continued success! #JTO20

Post attachment
Stephen V Liu, MD avatar
⟳ JTO & JTO CRR retweeted
Stephen V Liu, MD@StephenVLiu·Nov 9

Phase II results for soxataltinib, CNS penetrant selective RET inhibitor, in NSCLC @JTOonline. As 1L therapy, RR 89.3%, TTR 0.9m, PFS 19.3m, intracranial RR 100% (n=4) and TRAEs included AST elevation (71%, G3+ 9%) and notably, diarrhea (79%, G3+ 18%). jto.org/article/S1556-0864(2…

JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 9

Amid ongoing debate about the optimal technical strategy of performing ctDNA-based assays to detect minimal residual disease after surgery, Cui et al. put the methods to the test. In 417 plasma samples from 84 patients with stages I-III LC, they found that personalized tumor-informed assays provided the best prediction for disease recurrence. Dive into the details here: bit.ly/4swRBpR #ctDNA #LungCancer #LungCancerResearch #JTO

Post attachment
JTO & JTO CRR avatar
JTO & JTO CRR@JTOonline·Nov 8

Thank you to Graham Warren for ten years of helping JTO serve as a trusted resource for the global thoracic oncology community! #JTO20

Post attachment